VVOS — Vivos Therapeutics, Inc.

Vivos Therapeutics Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Increased 76% year-over-year to $6.8 million, up from $3.9 million in Q3 2024, and 78% sequentially from Q2 2025.
• Service Revenue: Contributed $2.7 million, primarily from the acquisition of Sleep Center of Nevada (SCN), with $2.2 million from OSA sleep testing services.
• Cost of Sales: Increased 87% to approximately $2.8 million, reflecting integration costs related to SCN.
• Gross Profit: Rose to $3.9 million, with a gross margin of 58%, slightly down from 60% in Q3 2024.
• Net Loss: Increased to $5.4 million for Q3 and $14.3 million for the first nine months of 2025.
• Cash Position: As of September 30, 2025, cash and cash equivalents were $3.1 million, with total liabilities at $23.1 million.

2. Strategic Updates and Business Highlights

• The acquisition of SCN marks a pivotal shift towards a sleep medical practice model, enhancing revenue from OSA diagnostics and treatments.
• Vivos established Sleep and Airway Medicine Centers (SAMC) in two locations in Nevada, which are expected to drive future revenue growth.
• The company is focusing on expanding its operational capacity and hiring additional medical and dental providers to meet growing demand.
• Vivos is exploring further acquisitions and affiliations with sleep centers, aiming to replicate its successful model in new markets.

3. Forward Guidance and Outlook

• Management anticipates continued revenue growth as operational capacity expands and new providers are onboarded, projecting a 3- to 6-month ramp-up period for revenue generation post-hiring.
• The company expects to reach cash flow breakeven as SAMC centers become fully operational and profitable.
• Future initiatives include expanding diagnostic services, launching a pediatric OSA program, and collaborating with specialty medical groups.

4. Bad News, Challenges, or Points of Concern

• Increased operating expenses due to upfront investments in personnel and integration costs, which may impact short-term profitability.
• The company is currently constrained by the number of licensed dental providers, limiting its ability to fully capitalize on demand.
• There are concerns about the time required for provider credentialing, which can delay revenue generation.
• The reliance on a single acquisition (SCN) poses risks if the anticipated growth does not materialize as expected.

5. Notable Q&A Insights

• Management indicated that revenue growth is expected to continue as new providers are licensed and deployed, with a potential 6-month ramp to full capacity.
• The company aims for contribution margins of 50-60% at steady state for SAMC operations.
• Investors were advised to monitor the progress of new affiliations and the overall scalability of the business model as indicators of future growth potential.
• There was a focus on the competitive landscape, particularly the ongoing challenges posed by traditional CPAP treatments and the opportunity for Vivos to capture market share with its innovative solutions.

Overall, Vivos is optimistic about its strategic pivot and the potential for significant growth in the sleep disorder treatment market, despite facing operational challenges in the short term.